Institution Directory

Clinical trials at Roswell Park Comprehensive Cancer Center

Sites in Buffalo, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

527

Shown on this page

Current sort

Live official records

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Epcoritamab, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 68
States / cities: Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma
Interventions: Carboplatin, Nivolumab, Paclitaxel; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 579
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 381 more

Conditions: Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions: Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 124
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more

Conditions: Acute Myeloid Leukemia
Interventions: Debio 1562M; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
Interventions: Gilteritinib, Venetoclax, Azacitidine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 12 more

Conditions: Prostate Carcinoma
Interventions: Biopsy of Prostate, Magnetic Resonance Imaging, Micro-ultrasound Imaging; Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Metastatic Malignant Neoplasm in the Brain
Interventions: Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery; Procedure · Other · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 208
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more

Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 280
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more

Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Interventions: Bevacizumab, Carboplatin, Ixabepilone, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 230
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more

Conditions: Psychiatric Disorder
Interventions: Cranial Electrical Stimulation (CES), Discussion, Health and Wellness Coach, Informational Intervention, Sham Intervention; Procedure · Other · Behavioral
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 170
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more

Conditions: Pancreatic Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 50 Years to 75 Years
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2034
U.S. locations: 413
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more

About this Roswell Park Comprehensive Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Roswell Park Comprehensive Cancer Center in Buffalo, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Roswell Park Comprehensive Cancer Center

Filter and sort this campus

Live official records

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

About this Roswell Park Comprehensive Cancer Center institution page